Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
you are here: HomeNewsBusiness

Glenmark introduces medication to prevent chemotherapy-induced nausea

The company has introduced IV injection formulation Akynzeo IV in a fixed dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg) and is available as a ready-to-dilute IV injection, the Mumbai-based drug maker said in a statement.

January 23, 2023 / 11:36 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Glenmark Pharmaceuticals on Monday said it has launched a medication for prevention of chemotherapy-induced nausea and vomiting, under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.

The company has introduced IV injection formulation Akynzeo IV in a fixed dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg) and is available as a ready-to-dilute IV injection, the Mumbai-based drug maker said in a statement.

It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV).

The drug is already being marketed in the EU, the US, and Australia.